Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab and Semi-Vegetarian Diet for Ulcerative Colitis
NCT03309865Phase 1Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Dec 2017
- Primary completion
- Aug 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vedolizumab in ulcerative colitis (UC), sponsored by Mayo Clinic. Primary endpoint: Clinical response at 6 weeks. Planned start Dec 2017; status: withdrawn.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03309865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03309865.